Secura Bio Announces Journal of Clinical Oncology Publication of Final Results of Duvelisib PRIMO Phase 2 Trial in Relapsed/Refractory Peripheral T-cell Lymphoma

PUBLISHED Monday, April 27, 2026 · secura bio

AI BRIEFING

⬤ Secura Bio's duvelisib shows promising results in treating relapsed/ refractory peripheral T-cell lymphoma
⬤ The Phase 2 trial demonstrated clinically meaningful response rates, including a substantial proportion of complete responses
⬤ Duvelisib was found to be effective in a heavily pretreated population